Category: Cardiovascular Systems Inc.
Cardiovascular Systems begins enrollment in its COAST trial, evaluating the micro crown Orbital Atherectomy System in patients with hard-to-treat coronary artery disease.
Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.
Here's a look at some of the top legal news stories for medical device companies this week: Jury: Medtronic owes bone cement acquisition $15M; North Carolina DA probes Cardiovascular Devices; Negligence claims stand in Medtronic Infuse lawsuits; Judge slaps sanction on J&J's lawyers in Ethicon pelvic mesh case; Stryker must face class action employment claims.
Cardiovascular Systems' shares drop as Boston Scientific positions itself as a peripherals market rival with the $415 million acquisition of Bayer AG's interventional business.
Boston Scientific's (NYSE:BSX) $415 million acquisition of Bayer AG's interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
The district attorney for western North Carolina investigates Cardiovascular Systems for possible violations of the False Claims Act.
Cardiovascular Systems (NSDQ:CSII) late last week became the latest medical device company to reveal a federal probe into possible marketing or False Claims Act violations.
Here's a look at some of the top Wall Street stories for medical device companies this week.
, Cardiovascular Systems Inc.
, Edwards Lifesciences
, Endo Health
, Hansen Medical Inc.
, Intuitive Surgical Inc.
, Johnson & Johnson
, Morgan Stanley
, Accuray Inc.
, GI Dynamics
Planned investments take a big chunk out of Cardiovascular Systems' bottom line, but a 32% boost in sales prompts some Wall Street love.
Cardiovascular Systems' (NSDQ:CSII) revenues soared in its 3rd quarter, driven primarily by the popularity of the company's Stealth 360 device, a peripheral artery disease treatment system.